Safety evidence

Retatrutide side effects

Safety evidence for Retatrutide is limited by the available study designs and product formulations.

Evidence boundary

Reported events must be interpreted in the population, dose, route, and formulation that were actually studied.

Product quality

Research-vendor identity, purity, sterility, and stability are separate from compound-level safety evidence.

Not a risk clearance

An incomplete adverse-event record does not establish long-term safety.

Side Effects

Less common

Transient lipase elevations

Serious but rare

Acute pancreatitis (1 case in Phase 2) - discontinue if suspected
Gallbladder disorders (cholelithiasis, cholecystitis)
Hypersensitivity reactions

Class-level context

Retatrutide has no approved label. Trial exclusions and warnings known from approved GLP-1 medicines are useful context, but they should not be presented as Retatrutide-specific approved contraindications.